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background: Corifollitropin alfa, a fusion protein lacking LH activity, has a longer elimination half-life and extended time to peak levels than
recombinant FSH (rFSH). A single injection of corifollitropin alfa may replace seven daily gonadotrophin injections during the ﬁrst week of ovarian
stimulation.
methods: In this large, double-blind, randomized, non-inferiority trial the ongoing pregnancy rates were assessed after one injection of
150 mg corifollitropin alfa during the ﬁrst week of stimulation and compared with daily injections of 200 IU rFSH using a standard GnRH antagonist
protocol.
results: The study population comprised 1506 treated patients with mean age of 31.5 years and body weight of 68.6 kg. Ongoing pregnancy
rates of 38.9% for the corifollitropin alfa group and 38.1% for rFSH were achieved, with an estimated non-signiﬁcant difference of 0.9% [95%
conﬁdence interval (CI): 23.9; 5.7] in favor of corifollitropin alfa. Stratiﬁed analyses of pregnancy rates conﬁrmed robustness of this primary
outcome by showing similar results regardless of IVF or ICSI, or number of embryos transferred. A slightly higher follicular response with cor-
ifollitropin alfa resulted in a higher number of cumulus–oocyte-complexes compared with rFSH [estimated difference 1.2 (95% CI: 0.5; 1.9)],
whereas median duration of stimulation was equal (9 days) and incidence of (moderate/severe) ovarian hyperstimulation syndrome was the
same (4.1 and 2.7%, respectively P ¼ 0.15).
conclusion: Corifollitropin alfa is a novel and effective treatment option for potential normal responder patients undergoing ovarian stimu-
lation with GnRH antagonist co-treatment for IVF resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH.
The trial was registered under ClinicalTrials.gov identiﬁer NTC00696800.
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Corifollitropin alfa is the ﬁrst hybrid molecule with sustained
follicle-stimulating activity. Corifollitropin alfa is a recombinant fusion
protein composed of FSH and the carboxy terminal peptide (CTP) of
the hCG b-subunit (Fares et al., 1992). Like recombinant FSH (rFSH),
corifollitropin alfa interacts only with the FSH-receptor and lacks LH
activity(Lapoltetal.,1992;Fauseretal.,2009).However,corifollitropin
alfa has an approximately 2-fold longer elimination half-life (t1/2) and an
almost 4-fold extended time-interval (tmax) to peak serum levels (Cmax)
(Duijkers et al., 2002). Due to this pharmacokinetic proﬁle, corifollitro-
pin alfa can function as a sustained follicle stimulant with a similar phar-
macodynamic proﬁle as rFSH, but with the ability to initiate and sustain
multiple follicular growth for an entire week. Consequently, a single s.c.
injectionoftherecommendeddoseofcorifollitropinalfacanreplacethe
ﬁrst seven injections of any daily FSH preparation in an ovarian stimu-
lation treatment cycle prior to IVF.
The need for simpliﬁed treatment approaches which will lessen the
treatment burden of IVF is self-evident. The IVF treatment process
itselfisincreasinglyrecognizedascontributingtothephysical,psychologi-
cal and emotional burden on infertility patients (Boivin and Takefman,
1996; Cousineau and Domar, 2007). Infertile patients experience high
levels of distress and their level of anxiety and depression is equivalent
to that experienced by women with cancer or heart disease (Domar
etal.,1993).AnumberofIVFstudiesinwhichtreatmentcostswerereim-
bursedhaveneverthelessreporteddrop-outrateswellabove50%before
completingtheircoverednumberofcycles(Landetal.,1997;Oliviusetal.,
2002; Schro ¨der et al., 2004), largely due to the psychological impact of
treatment (Olivius et al., 2004; Rajhkowa et al., 2006). Thus, the
primary reason for treatment discontinuation is not based on physician
recommendation, but is because patients are too distressed to continue
(Hammarberg et al., 2001).
In GnRH antagonist co-treatment stimulation protocols, the dur-
ation of stimulation is reduced compared with GnRH agonist proto-
cols and less FSH is used to reach the same criteria for
administering hCG (Tarlatzis et al., 2006). Interestingly, a prospective
cohort study comparing a GnRH antagonist protocol with a conven-
tional long GnRH agonist protocol demonstrated a signiﬁcantly
reduced drop-out rate in the antagonist group, indicating that the
impact of the treatment strategy is an important factor determining
the risk of drop-out (Verberg et al., 2008). Clearly, simple treatment
regimens that lessen the burden of IVF improve the overall patient
experience, and encourage lower drop-out rates (Olivennes 2003,
Heijnen et al., 2004, Pennings and Ombelet, 2007). Last but not
least, fewer injections to be given may improve drug compliance
and/or prevent errors during drug administration.
Developing corifollitropin alfa in a short GnRH antagonist protocol
may add to the further reduction of the treatment intensity experi-
enced by patients undergoing ovarian stimulation for IVF. Following
the dose-ﬁnding trial (The Corifollitropin alfa Dose-ﬁnding Study
Group, 2008) and subsequent pharmacokinetic/pharmacodynamic
modeling (De Greef et al., 2007) it was concluded that the rec-
ommended dose of corifollitropin alfa was 100 mg for subjects with
body weight of  60 kg and 150 mg for subjects with body weight of
.60 kg. Based on simulations, these two dosages of corifollitropin
alfa will provide the same exposure and the same degree of ovarian
response in the recommended body weight groups. After a single
injection of corifollitropin alfa on menstrual cycle day 2 or 3, treatment
may be continued with a daily dose of rFSH from stimulation day 8
onwards if needed. Patients who reach the criteria of triggering ﬁnal
oocyte maturation prior to day 8 of stimulation do not require any
daily FSH to be administered.
First and foremost the question that needs to be addressed is
whether the new corifollitropin alfa regimen results in the same
success rates as a daily FSH regimen with GnRH antagonist
co-treatment. To this end, the aim of the ENGAGE trial was to inves-
tigate whether the ongoing pregnancy rates of the new corifollitropin
alfa regimen were comparable to a daily rFSH regimen in patients
undergoing ovarian stimulation prior to IVF. The sample size required
to sufﬁciently power this trial for ongoing pregnancy rate as a primary
end-point renders this the largest double-blind randomized trial in the
ﬁeld of assisted reproductive technology (ART) to date.
Materials and Methods
The ENGAGE trial was a multi-center, randomized, double-blind double-
dummy, non-inferiority clinical trial involving 14 centers in North America
(13 centers in USA and one in Canada) and 20 centers in Europe (three in
Spain and The UK; two in Belgium, Czech Republic, Finland, France,
Norway, and Sweden; one in Denmark and The Netherlands) and con-
ducted between June 2006 and January 2008.
The study was approved by the Independent Medical Ethics Committee
or Institutional Review Board for each center as well as by the responsible
Health Authority and was conducted in accordance with the Declaration
of Helsinki, International Conference on Harmonization guidelines for
Good Clinical Practice, and local regulatory requirements. An Independent
Data Safety Monitoring Board was appointed to monitor the safety of sub-
jects participating in the trial, and written informed consent was provided
by all patients.
Study population
Women aged 18–36 years with a body weight of more than 60 kg up to
and including 90 kg, a BMI of 18–32 kg/m
2, a menstrual cycle length of
24–35 days, access to ejaculatory sperm and an indication for controlled
ovarian stimulation (COS) before IVF or ICSI were eligible to enroll in the
study. Patients who had a (history of) an endocrine abnormality, an abnor-
mal outcome of blood biochemistry or hematology, an abnormal cervical
smear, a chronic disease, relevant ovarian-, tubal- or uterine-pathology
that could interfere with the COS treatment (e.g. endometrioma
.0 mm or ﬁbroids  5 cm), embryo implantation or pregnancy were
not to be included in the trial. Patients who had a history of ovarian hyper-
response (more than 30 follicles  11 mm) or ovarian hyperstimulation
syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral
follicle count (AFC) of more than 20 on ultrasound (,11 mm, both
ovaries combined) were excluded from participation. Other exclusion cri-
teria included a previously low ovarian response to FSH or hMG treatment
(i.e. cycle cancelled due to insufﬁcient ovarian response or less than four
oocytes obtained), an FSH or LH over 12 IU/L in the early follicular phase,
more than three consecutive unsuccessful IVF cycles since the last ongoing
pregnancy, a history of recurrent miscarriage (three or more), or currently
smoking more than ﬁve cigarettes per day.
Study design
The trial was designed as a randomized, double-blind, double-dummy,
active-controlled, non-inferiority trial to compare the efﬁcacy of a single
injection of corifollitropin alfa during the ﬁrst week of stimulation with
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during COS. Randomization to one of the two treatment arms (1:1 ratio)
was done per center and stratiﬁed by age (,32 and 32 years) by central
remote allocation using randomly permutated blocks with an undisclosed
ﬁxed block size of four.
Stimulation regimen and ART procedures
All patients were to start their treatment cycle on menstrual cycle day 2 or
3 as depicted in Fig. 1. Per protocol all injections were to be administered
in the morning. Patients started stimulation with a single s.c. injection of
150 mg (0.5 mL) corifollitropin alfa (NV Organon, The Netherlands) or
matching placebo. Injections could be done by the patient herself, her
partner or the medical staff. To conceal treatment allocation all patients
also started daily s.c. injection of 200 IU rFSH (follitropin beta, Pure-
gon
w/Follistim
w AQ Cartridge, NV Organon, The Netherlands) or
matching placebo on the same day (Stimulation Day 1) using the Pure-
gon
w/Follistim Pen
w. Daily active or placebo (‘dummy’) rFSH injections
were continued through the ﬁrst 7 days of stimulation. The chosen refer-
ence dose of 200 IU rFSH daily was considered the optimal choice for the
included patient population weighing over 60 kg in a global trial combining
European and North American sites. This dose was ﬁxed for the ﬁrst 5
days of stimulation. This is in line with the suggestion by Arce et al.
(2005) who recommended a ﬁxed starting dose for at least 5–7 days in
all efﬁcacy trials as only after such period the impact of the administered
FSH dose can be adequately evaluated. Moreover, this is considered
appropriate because daily FSH only reaches steady state after 3–5 days
of dosing (Mannaerts et al., 1993). A reduction of the rFSH dose was
allowed from stimulation day 6 onward in case of too high an ovarian
response, at the discretion of the investigator. When no follicle
 11 mm was visible on ultrasound scan (USS) before injection on stimu-
lation day 8 the cycle was to be cancelled due to insufﬁcient ovarian
response. From stimulation day 8 onwards, treatment in both groups
was continued with a daily s.c. dose of (active) rFSH up to and including
the day of hCG administration. The maximum rFSH dose to continue
treatment after the ﬁrst 7 days was 200 IU but the dose could be
reduced when desired. For normal responders, the recommended daily
dose of rFSH was 150 IU. Whenever deemed required by the investigator,
rFSH administration could be withheld for a maximum of 3 days (coasting)
up to and including the day of hCG administration. In case there was a too
high ovarian response as per the investigator’s opinion, the cycle could be
cancelled at any time. However, in case of a risk for OHSS, deﬁned as
more than 30 follicles of  11 mm on USS, hCG was always to be withheld
and the treatment cycle was to be cancelled per protocol. The maximum
total duration of stimulation was 19 days.
TopreventprematureLHsurgestheGnRHantagonistganirelix(0.25 mg,
Orgalutran
w/ganirelix acetate injection, NV Organon, The Netherlands)
was administered once daily s.c. starting on stimulation day 5 up to and
including the day of hCG. Urinary hCG (10 000 IU) was administered to
induce ﬁnal oocyte maturation as soon as at least three follicles of
 17 mm were observed by USS. Investigators were allowed to delay
hCG administration for 1 day when preferred for practical reasons. In
casetherewasatoohighovarianresponseintheopinionoftheinvestigator,
a lower dose (5000 IU hCG) could be used. About 34–36 h thereafter,
oocyte retrieval followed by standard IVF or ICSI was to be performed.
Embryo quality was evaluated for all available embryos on day 3 of culture
by the local embryologist using a protocol-deﬁned guideline based on the
following parameters: number of blastomeres, degree of fragmentation,
blastomere size uniformity and presence or absence of multinucleation.
Embryos graded as grade 1 (6–10 cells, no fragmentation and equal blasto-
mere size) or grade 2 (allowing up to 20% fragmentation) were qualiﬁed as
goodqualityembryos.Thequalityof embryoscontinued in cultureafter day
3 was reassessed on the day of transfer or freezing using grading criteria
appropriate for the stage of embryo culture. At embryo transfer, 3 or 5
days after oocyte retrieval, one or two embryos were to be transferred.
The decision on the day of transfer and number of embryos to be trans-
ferred was made by the investigator. To support implantation and early
pregnancy, luteal phase support with progesterone (at least 600 mg/day
vaginally or at least 50 mg/day i.m., to be prescribed locally) was started
on the day of oocyte retrieval and continued for at least 6 weeks, or
either up to menses or up to a negative pregnancy test performed at least
14 days after embryo transfer.
Figure 1 Graphical illustration of the treatment regimens applied in this trial. Upper panel depicts investigational group (corifollitropin alfa), lower
panel depicts reference group (rFSH).
rFSH: recombinant FSH, P: progesterone.
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Before the start of ovarian stimulation, pregnancy was excluded by means
of an hCG test, a blood sample was obtained for hormone assessments,
and USS was performed to measure and count visible follicles. Local tol-
erance parameters (pain, itching, swelling and redness) were assessed
by the clinical staff 30 min after injection for both (placebo) corifollitropin
alfa and (placebo) rFSH injection sites. Patients returned to the clinic for
USS and blood sampling on stimulation days 5 and 8, and then daily up
to and including the day of hCG administration for USS only. Additional
blood samples were collected on the day of embryo transfer and 2
weeks after embryo transfer. Patients who left the study prior to
embryo transfer were sampled for hormones and antibody assessments
at the day of discontinuation and 2 weeks thereafter.
Validated immunoassays were performed at a central laboratory
(Schering-Plough, Oss, The Netherlands and Waltrop, Germany) to
measure serum levels of FSH, LH, estradiol (E2), progesterone, inhibin-B
and antibodies against corifollitropin alfa (Devroey et al., 2004).
End-points
Ongoing pregnancy, deﬁned as presence of at least one fetus with heart
activity at least 10 weeks after embryo transfer as assessed by USS or
Doppler, or conﬁrmed by live birth, was the primary end-point for this
trial. This can be considered as the best and closest estimate of the ulti-
mate treatment success (delivery of a healthy baby) and excludes subjects
with a miscarriage during the ﬁrst 10 weeks of pregnancy (Arce et al.,
2005). In addition, the number of retrieved oocytes was considered as
co-primary end-point in this trial being more proximately related to the
pharmacological effect of the two treatment regimens which are compared
in this trial. Other clinical outcome parameters evaluated included dose of
rFSH required, duration of stimulation, number and size of follicles, serum
hormone levels, fertilization rate, number and quality of embryos obtained
and pregnancy rates. The ultimate live birth rate, the health of the off-
spring, and outcomes achieved with spare, frozen embryos will be
reported separately when follow-up has been completed.
Occurrence of (serious) adverse events, including moderate and severe
OHSS as per World Health Organization criteria (WHO, 1973), outcome
of local tolerance and immune response assessments were evaluated as
safety end-points.
Statistical analysis
The sample size needed for this trial was largely determined by the chosen
pre-deﬁned non-inferiority margin (i.e. smaller margin requires larger
sample size to maintain the same power) but also depended on the antici-
pated ongoing pregnancy rate (i.e. higher pregnancy rate requires larger
sample size) to be expected in a combined trial comprising sites in
Europe, USA and Canada. For this global trial a non-inferiority margin of
8% was considered appropriate. This implies that if the lower bound of
the 95% conﬁdence interval (CI) for the estimated difference in ongoing
pregnancy rates between treatment groups (corifollitropin alfa minus
rFSH) was determined to be above 28%, corifollitropin alfa could be con-
sidered non-inferior to rFSH. Although such a difference would be relevant
for an individual subject seeking to become pregnant after IVF treatment it
should be considered in the context of existing differences in routine preg-
nancy rates between centers, countries and regions (Gleicher et al., 2006,
2007). A sample size of at least 1380 subjects was calculated to be the
minimum required to demonstrate non-inferiority with a power of 90%,
using a 28% non-inferiority margin for the lower limit of the two-sided
95% CI, and assuming an ongoing pregnancy rate of 30%. Based on
these data, a minimum of 700 subjects per group, in total at least 1400
subjects, were to be randomized which makes this the largest double-blind
comparative randomized trial performed to date.
For analysis of the primary end-point, ongoing pregnancy, the treatment
groups were formally compared with a generalized linear model for the
ongoing pregnancy rate including covariates treatment group, age
(,32 years,  32 years) and region (Europe, North America). The differ-
ence between the two treatment groups (corifollitropin alfa 2 rFSH) and
its associated two-sided 95% likelihood-based CI was estimated and a pre-
deﬁned non-inferiority margin of 8% was applied. Additional explorative
analyses were performed to investigate robustness of the primary end-
point results. No adjustment for multiplicity to correct for repeated
testing was performed.
The number of cumulus–oocyte-complexes retrieved was deﬁned as
co-primary end-point in this trial. As there is an optimal range of
oocytes obtained in response to ovarian stimulation, below and above
which the success rates of IVF are compromised (Van der Gaast et al.,
2006) equivalence testing was deemed appropriate. Therefore, equival-
ence margins for the difference in the number of oocytes retrieved
were predeﬁned to be 23 and þ5 oocytes. If the new corifollitropin
alfa regimen resulted in three or more oocytes less than the reference
treatment, such difference was considered as clinically relevant because
three oocytes usually result in one good quality embryo for transfer or
freezing. Anticipating obtaining an average of 12–13 oocytes with the
applied rFSH doses in the reference group, an excess of more than ﬁve
oocytes would be undesirable as patients with more than 18 oocytes
retrieved are described to be at increased risk of developing OHSS (Papa-
nikolaou et al., 2006; Verwoerd et al., 2008). Hence, an upper margin of
þ5 oocytes is applied for the difference in the number of oocytes
retrieved between the treatment groups. The treatment groups were for-
mally compared using analysis of variance for the number of oocytes
including covariates treatment group, age (,32 years versus  32 years)
and center. The estimate of the difference between the two treatment
groups and its associated two-sided 95% CI was given. In case the 95%
CI of the difference exceeded 23o rþ5 oocytes corifollitropin alfa treat-
ment was not considered equivalent to the rFSH treatment.
Efﬁcacy analyses are based on the intention-to-treat (ITT) population
entailing all patients randomized and treated, analyzing them according
to their allocated treatment (i.e. ‘as randomized’). Both ITT and per pro-
tocol (PP) analyses were performed (see Supplementary Data), but as the
results were very similar, only the ITT results are presented here. The
main efﬁcacy analyses were performed ‘per started cycle’ (i.e. including
all subjects who started treatment regardless whether they discontinued)
as this provides the most conservative efﬁcacy estimates as it also accounts
for any unintended interference of premature cycle cancellations. For
safety end-point analyses, patients are grouped ‘as treated’ which
implied that three patients (one randomized to corifollitropin alfa and
two patients to rFSH) treated inadvertently with the wrong (comparator)
medication type are analyzed according to the treatment they actually
received. Statistical signiﬁcance was set at P , 0.05.
Results
A total of 1696 patients signed informed consent for eligibility evalu-
ation and participation in this trial (Fig. 2). Subsequently a total of
187 patients failed screening or dropped out due to personal
reasons prior to treatment allocation. Eventually, 1509 patients were
randomized to one of the two treatment groups of which 1506
patients actually started stimulation. The remaining three patients
were discontinued prior to the start of treatment (one for personal
reasons and two were found to violate entry criteria after randomiz-
ation but before commencing treatment).
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characteristics, USS ﬁndings and hormone proﬁles were comparable
in the two groups (Table I). Mean age (SD) of the patients included
in this trial was 31.5 (3.3) years, body weight was 68.6 (7.5) kg and
BMI was 24.8 (2.7) kg/m
2. The average duration of infertility was
3.3 (2.3) years and for 74% of the patients this was their ﬁrst treat-
ment cycle. On stimulation day 1, no differences were observed
between the treatment groups in the basal AFC or baseline serum
hormone levels (Table I).
Primary end-point: ongoing pregnancy rate
Results of the primary end-point analyses are presented in Table II.
High ongoing pregnancy rates of 38.9% for the corifollitropin alfa
group and 38.1% for the rFSH group were obtained per started
cycle. The estimated treatment difference, adjusted for age group
(,32 years,  32 years) and region (Europe, North America), was
þ0.9% [95% CI: (23.9; 5.7)] in favor of corifollitropin alfa.
Co-primary end-point: number of cumulus–
oocyte-complexes retrieved
The number of cumulus–oocyte-complexes retrieved was deﬁned as
co-primary end-point in this trial. The mean (SD) number of oocytes
retrieved in the corifollitropin alfa group was 13.7 (8.2) which was
higher than the mean of 12.5 (6.7) obtained in the rFSH group
(Table II). The estimated treatment difference was 1.2 oocytes in
favor of corifollitropin alfa (P ¼ 0.001), while the 95% CI was (0.5;
1.9). This indicates that the number of oocytes retrieved in the two
treatment groups was at least equivalent based on the pre-deﬁned
equivalence range.
Other clinical outcome parameters
The median duration of stimulation was 9 days for both treatment
groups, which implied patients treated with corifollitropin alfa
needed on average 2 days of rFSH to complete their treatment
cycle (Table III). Per protocol, the dose of (placebo) rFSH could be
reduced (not increased) from stimulation day 6 onwards. Dose
decreases on stimulation days 6 or 7 were recorded slightly more
often in the corifollitropin alfa group (85/750, 11.3%) than in the
rFSH group (62/741, 8.4%). Coasting by withholding rFSH for 2 or
more days was applied in 1.6% [12/733, 95% CI: (0.7; 2.6)] of patients
in the corifollitropin alfa group and in 2.2% [16/741, 95% CI: (1.0;
3.3)] of patients in the rFSH group. A ﬁxed dose regimen from stimu-
lation day 8 up to but not including the day of hCG was used in 72.1%
(413/573) of the corifollitropin alfa group and 81.0% (430/531) of the
rFSH group. After a single injection of corifollitropin alfa, 249 out of
756 patients (32.9%) reached the criteria for giving hCG before or
on stimulation day 8: the ongoing pregnancy rate for this subgroup
of patients was 44.0%.
Eventually, 97.0% of the patients in the corifollitropin alfa group and
98.8% of the rFSH group received hCG to induce ﬁnal oocyte matu-
ration. The vast majority received 10 000 IU hCG (76.9% (581/756)
and 85.6% (642/750) of the patients in the corifollitropin alfa and
rFSH group, respectively), while a dose of 5000 IU hCG was used
........................................................................................
Table I Demographics, fertility characteristics and
baseline (stimulation day 1) ultrasound scan (USS) and
serum hormone levels per treatment group
(intent-to-treat population)
Corifollitropin
alfa (n 5 756)
rFSH
(n 5 750)
Demographics
Age (years) 31.5 (3.3) 31.5 (3.2)
Body weight (kg) 68.8 (7.6) 68.4 (7.3)
BMI (kg/m
2) 24.8 (2.8) 24.8 (2.7)
Race, n (%)
Asian 21 (2.8) 21 (2.8)
Black 33 (4.4) 28 (3.7)
Caucasian 643 (85.1) 650 (86.7)
Other 59 (7.8) 51 (6.8)
Fertility characteristics
Primary infertility, n (%) 403 (53.3) 393 (52.4)
Duration of infertility (years) 3.3 (2.4) 3.2 (2.2)
Cause of infertility
a), n (%)
Male factor 388 (51.3) 347 (46.3)
Tubal factor 198 (26.2) 191 (25.5)
Endometriosis 109 (14.4) 115 (15.3)
Other/unexplained 246 (32.5) 262 (34.9)
First IVF cycle, n (%) 569 (75.3) 552 (73.6)
Stimulation day 1
Total ovarian volume (mL)
b) 13.2 (8.1) 13.2 (7.1)
Basal AFC (,11 mm) 12.3 (4.6) 12.4 (4.4)
FSH (IU/L) 6.7 (2.1) 6.6 (1.9)
LH (IU/L) 4.8 (2.0) 4.7(1.8)
E2 (pmol/L) 126.1 (39.3) 124.8 (37.4)
Progesterone (nmol/L) 1.8 (1.3) 1.8 (1.4)
AFC: antral follicle count, E2: estradiol, rFSH: recombinant FSH.
Numbers are mean (SD) unless otherwise indicated.
a)A patient can have multiple causes of infertility.
b)According to the formula for a polate ellipsoid: 0.523   longitudinal  
antero-posterior   transverse diameters as measured per transvaginal ultrasound.
Figure 2 Flow chart showing the number of participants at each
stage of the clinical trial.
High IVF success rates with corifollitropin alfa 3067for 19.8% (150/756) and 13.1% (98/750) of the respective groups.
Only the most frequent reasons for discontinuation prior to hCG are
mentioned. In total, 23 (3.0%) of the patients in the corifollitropin
alfa group and 7 (0.9%) of the patients in the rFSH group discontinued
prior to hCG. In the rFSH group, 2 patients discontinued after the
oocyte retrieval procedure, but it appeared that they had not received
hCG. Taking this into account, totals add up correctly to the number
of subjects treated with hCG (733 ¼ 756223, 741 ¼ 7502722).
.............................................................................................................................................................................................
Table II Primary end-points of the ENGAGE trial: ongoing pregnancy rate (assessed at least 10 weeks after embryo
transfer) and the mean (SD) number of cumulus–oocyte-complexes retrieved (intent-to-treat population)
Corifollitropin alfa (n 5 756) rFSH (n 5 750) Estimated difference
a) [95% CI], P-value
Ongoing pregnancies (n) 294 286
Per started cycle (%) 38.9% 38.1% 0.9 [23.9; 5.7], P ¼ 0.71
Per embryo transfer (%) 43.8% 40.6% 3.1 [22.0; 8.2], P ¼ 0.24
Cumulus–oocyte-complexes
Per started cycle 13.7 (8.2) 12.5 (6.7) 1.2 [0.5; 1.9], P ¼ 0.001
Per oocyte retrieval 14.1 (7.9) 12.7 (6.7) 1.6 [0.8; 2.3], P , 0.001
P-value corresponds to the test whether the treatment difference equals zero.
a)Estimated treatment difference (corifollitropin alfa 2 rFSH) adjusted for covariates.
.............................................................................................................................................................................................
Table III Clinical parameters from stimulation phase up to embryo transfer (intent-to-treat population)
Corifollitropin alfa (n 5 756), median (range) rFSH (n 5 750), median (range)
Stimulation characteristics
a)
Total dose of rFSH (IU) 400 (0–2000) 1800 (400–2800)
Total dose of rFSH from day 8 onwards (IU) 400 (0–2000) 400 (0–1400)
Total duration of stimulation (days)
b) 9 (6–18) 9 (6–15)
Follicles, day of hCG
a)
 11 mm 16.0 (7.0) 13.9 (6.1)
 15 mm 9.6 (4.8) 8.7 (4.0)
 17 mm 5.7 (3.2) 5.6 (2.9)
Serum parameters, day of hCG
a)
FSH (IU/L) 12.5 (3.3) 11.6 (2.8)
LH (IU/L) 1.4 (1.8) 1.9 (1.6)
E2 (pmol/L) 5508.8 (3469.8) 5165.3 (2998.2)
Inhibin-B (pg/mL) 610.3 (492.3) 614.8 (435.6)
Progesterone (nmol/L) 3.0 (2.1) 3.2 (1.5)
Clinical outcome per started cycle
Oocytes retrieved, ICSI only 13.8 (7.6) 12.1 (6.3)
Metaphase II oocytes (ICSI only),% of total 10.8 (6.5), 78.9 (18.9) 9.2 (5.1), 77.4 (18.1)
Fertilization rate (%)
c,d) 66.0 (23.4) 67.6 (22.9)
Total number of embryos obtained (day 3)
c) 8.3 (5.6) 7.4 (4.8)
Excellent (top) quality embryos (grade 1)
c) 2.6 (3.4) 2.5 (3.4)
Good quality embryos (grade 1þ2)
c) 4.6 (4.3) 4.4 (3.9)
Single embryo transfer (%)
d) 25.7 27.0
Embryos transferred
e) 1.7 (0.4) 1.7 (0.4)
Embryos cryopreserved
f) 4.3 (3.6) 3.9 (2.7)
Numbers are mean (SD) unless otherwise indicated.
a)Restricted to patients with hCG injection.
b)Number of days up to and including the day of hCG administration.
c)Restricted to patients with IVF and/or ICSI.
d)Deﬁned as 100 times the number of mature oocytes (with two pronuclei) obtained divided by the number of oocytes used for fertilization.
e)Restricted to patients with embryo transfer.
f)Restricted to patients with cryopreserved embryos.
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 11 mm on USS was 16.0 (7.0) for the corifollitropin alfa group
and 13.9 (6.1) for the rFSH reference group (Table III). When com-
paring serum hormones on the day of hCG administration comparable
levels were observed in both treatment groups. Oocyte retrieval was
performed in 96.8% of the patients in the corifollitropin alfa group and
98.9% in the rFSH group. A higher mean number of cumulus–oocyte-
complexes was retrieved in the corifollitropin alfa group (Table II).
Oocyte maturity was assessed for ICSI patients and also showed a
higher number and percentage of mature oocytes (Table III) in the
corifollitropin alfa group (mean 10.8, 78.9%) compared with the
rFSH group (mean 9.2, 77.4%). A comparable fertilization rate was
observed between the groups resulting in a mean (SD) of 8.3 (5.6)
embryos obtained on day 3 of culture in the corifollitropin alfa
group and 7.4 (4.8) embryos in the rFSH group for patients with
IVF and/or ICSI. Embryo quality, as assessed by the local embryolo-
gist, was similar in both groups.
Ultimately, 672 patients (88.9%) in the corifollitropin alfa group and
704 patients (93.9%) in the rFSH group had embryo transfer in this
trial. Between hCG administration and embryo transfer 39 out of
756 patients (5.2%) in the corifollitropin alfa group and 34 out of
750 (4.5%) patients in the rFSH group were discontinued as a result
of too few or too low quality oocytes, lack of fertilization or poor
embryo development. During this period 6/756 patients (0.8%) in
the corifollitropin alfa group and none in the rFSH group were discon-
tinued due to a too high ovarian response or risk of OHSS. Although
no embryo transfer was performed, fertilized oocytes or embryos
were cryopreserved for all these six patients. When embryo transfer
was performed, single embryo transfer was carried out in slightly more
than a quarter of all transfers (Table III). On average, 1.7 (0.4)
embryos were transferred in both treatment groups. For 51.7 and
53.2% of the patients in the corifollitropin alfa and rFSH groups, a
mean (SD) of 4.3 (3.6) and 3.9 (2.7) supernumerary embryos have
been cryopreserved, respectively.
In the corifollitropin alfa group 29.2% (221/756), and in the rFSH
group 30.3% (227/750), received only i.m. luteal phase progesterone
support, whereas respectively 52.0% (393/756) and 54.9% (412/750)
received only intravaginal progesterone support. Other subjects
received a combination of routes.
Pregnancy rates (conﬁrmed by positive hCG test) of 48.1 and 46.9%
were achieved in the corifollitropin alfa and rFSH groups, respectively,
followed by a comparable number of early pregnancy losses during the
ﬁrst 10 weeks after embryo transfer. Accordingly, similar ongoing
pregnancy rates were observed in both groups (Table IV). There
was no relevant difference in the ongoing pregnancy rates between
subjects who received the hCG injection on the same day that
three follicles  17 mm were observed (40.0 and 37.8% for corifolli-
tropin alfa and rFSH, respectively) versus subjects who received
hCG one day later (38.9 and 41.8% for corifollitropin alfa and rFSH,
respectively).
The robustness of this primary efﬁcacy outcome was explored in
speciﬁc subsets of patients grouped according to the ART
procedure-related factors, i.e. undergoing IVF or ICSI, having single
or double embryo transfer and having embryo transfer on day 3 or
day 5 (Fig. 3). The ongoing pregnancy rates in each subset were
similar for corifollitropin alfa and rFSH and there was no signiﬁcant
interaction with the type of treatment factor (IVF or ICSI), nor for
the number of embryos transferred (one or two). A borderline signiﬁ-
cant interaction with the type of treatment was only observed for the
factor day of transfer (P ¼ 0.045) as a result of higher pregnancy rates
for day 3 transfers with corifollitropin alfa whereas, for day 5 transfers,
the rFSH group showed marginally higher pregnancy rates (Fig. 3). The
subset analyses together conﬁrm the robustness of the observed
difference in pregnancy rates, independent of ART procedure-related
parameters.
Multiple pregnancy rates per ongoing pregnancy were 28.2% and
23.1% in the corifollitropin alfa group and the rFSH group, respectively
(Table IV). Although this difference is not signiﬁcant, it is in line with
the slightly higher implantation rate deﬁned as 100 times the
maximum number of gestational sacs divided by the number of
embryos transferred per subject for corifollitropin alfa [observed
means (SD) were 36.2% (41.6%) versus 32.2% (40.1%)].
Safety
In total, 16 subjects (2.1%) in the corifollitropin alfa group discontin-
ued due to a (serious) adverse event [SAE, two (0.3%) before and
14 (1.9%) following oocyte retrieval] as compared with three subjects
(0.4%) in the rFSH group [two (0.3%) before and one (0.1%) after
oocyte retrieval]. A total of 53 patients in the corifollitropin alfa-
treated group (7.0%) and 47 patients in the rFSH-treated group
(6.3%) developed OHSS in this trial. The incidences of (moderate/
severe) OHSS were 4.1% [31/755, 95% CI: (2.6; 5.6)] and 2.7%
[20/750, 95% CI: (1.5; 3.9)] for the corifollitropin alfa and rFSH
group, respectively, which was not signiﬁcant (Fisher exact P ¼ 0.15).
An equal number of 37 SAEs was reported for the corifollitropin
alfa and the rFSH-treated groups. Most frequently reported SAEs
were OHSS [14 patients (1.9%) treated with corifollitropin alfa and
9 patients (1.2%] treated with rFSH) and (ruptured) ectopic pregnancy
[7 patients (0.9%) and 9 patients (1.2%), respectively] while, respect-
ively, the most frequently reported AEs were procedural pain (22.3
........................................................................................
Table IV Clinical efﬁcacy outcomes per started cycle
(intent-to-treat population)
Corifollitropin
alfa (n 5 756)
rFSH
(n 5 750)
P-value
a)
Positive hCG test
b), n (%) 364 (48.1) 352 (46.9) 0.64
Clinical pregnancy
c), n (%) 322 (42.6) 308 (41.1) 0.57
Vital pregnancy
d), n (%) 302 (39.9) 293 (39.1) 0.75
Ongoing pregnancy
e), n (%) 294 (38.9) 286 (38.1) 0.71
Multiple pregnancy
f), n (%) 83 (28.2) 66 (23.1) 0.18
Early miscarriage
g), n (%) 27 (8.4) 21 (6.8) 0.55
a)P-values are based on Fisher’s exact test, except for ongoing pregnancy where the
P-value is based on the likelihood ratio test corresponding to the generalized linear
model with covariates treatment group, age class (,32 years,  32 years) and region
(Europe, North America).
b)Positive hCG test at least 14 days after embryo transfer or USS with at least one
gestational sac.
c)Clinical pregnancy: gestational sac on USS.
d)Vital pregnancy: gestational sac þ fetal heartbeat.
e)Ongoing pregnancy: vital fetus at least 10 weeks after embryo transfer or live birth.
f)Per ongoing pregnancy.
g)Per clinical pregnancy.
High IVF success rates with corifollitropin alfa 3069and 20.1%), pregnancy-related events including (missed) abortion
(13.8 and 11.2%), pelvic pain (12.1 and 12.3%), pelvic discomfort
(11.5 and 11.6%) and headache (10.5 and 15.2%). There were no
drug-related immune responses or moderate or severe local tolerance
reactions observed in this trial.
Discussion
The current ENGAGE trial was a double-blind, double-dummy trial
initiated to investigate whether the new corifollitropin alfa regimen
provides similar success rates compared with the current care. The
double-dummy approach guaranteed the blinding of medication
during the trial and prevented any bias in terms of treatment decisions.
Owing to the fact that the trial was powered to enable comparison of
the ongoing pregnancy rates as the primary study end-point, this is the
largest double-blind efﬁcacy trial in IVF performed to date. The
outcome of the trial provides compelling evidence of equal efﬁcacy
in terms of ongoing pregnancy rates, because the point estimates
i.e. 38.9 and 38.1% for the ongoing pregnancy rates were very close
for the two treatment groups and the 95% lower limit of the difference
was only 23.9%. Subset analyses of subjects undergoing IVF or ICSI
and of subjects who had single or double embryo transfer reveal con-
sistently high ongoing pregnancy rates, similar between the treatment
groups, which conﬁrm the robustness of the primary end-point. Even
though an equal number and quality of embryos were replaced in both
treatment groups, the multiple pregnancy rate in the corifollitropin alfa
group tended to be higher (þ4.4% absolute risk increase) than in the
reference group, which may be related to the slightly higher implan-
tation rate. This increase, although not signiﬁcant, cannot be ruled
out and may prove to be clinically relevant, given the low power of
the study to detect such a difference (c.22%). In this context, it
should be emphasized that both treatment arms used a ‘protocolized’
ﬁxed dose treatment regimen applying GnRH antagonist (ganirelix)
co-treatment, which conﬁrms the successful outcome of a patient-
friendly short GnRH antagonist protocol in corifollitropin alfa,
as well as rFSH, treatment cycles. In addition, one-third of the
patients treated with a single injection of corifollitropin alfa
reached the criteria for hCG injection prior to or on stimulation day
8, omitting the need for any additional FSH injections. The ongoing
pregnancy rate of this subset of good responder patients was
44.0%, thus 5.9% higher than the overall group of subjects treated
with corifollitropin alfa.
A hybrid molecule composed of human FSH and the CTP of hCG
was ﬁrst described by Boime and colleagues (Fares et al., 1992). In
subsequent clinical trials the new recombinant fertility hormone exhib-
ited a slower absorption (and subsequent rise to peak levels) and an
approximately 2-fold longer t1/2 compared with rFSH (Bouloux et al.,
2001; Duijkers et al., 2002). After corifollitropin alfa injection, peak
levels of FSH activity are reached within 2 days whereas steady state
levels with daily FSH are reached only after 4–5 days (Mannaerts
et al., 1996). These pharmacokinetic properties of corifollitropin alfa
create an opportunity to further simplify ovarian stimulation protocols
for IVF by omitting the need for daily gonadotrophin injections during
the ﬁrst week of stimulation (Fauser et al., 2009). In the current trial,
the difference in exposure during the ﬁrst days of stimulation may have
resulted in a slightly higher ovarian response in the corifollitropin alfa
treated patients, as previous trials with rFSH have shown that the
number of follicles recruited increases with the starting dose of
rFSH given (Wikland et al., 2001; Out et al., 2004). In view of the
equal pregnancy rates, the current trial does not suggest that the
higher exposure to FSH immunoactivity during the ﬁrst days of stimu-
lation interferes with the endometrial receptivity.
Figure 3 Ongoing pregnancy rates stratiﬁed for fertilization procedure, number of embryos transferred and day of transfer. Subset with double
embryo transfer includes three patients with three embryos transferred.
3070 Devroey et al.In this trial hormonal pretreatment with oral contraceptives or
supplementation with LH or hCG during the treatment phase was
not allowed per protocol. The efﬁcacy results in this large, global,
multi-center trial suggest that the amount of endogenous LH during
treatment with either corifollitropin alfa or daily rFSH in a standard
GnRH antagonist protocol is sufﬁcient to support high success rates
in terms of ongoing pregnancies (Cedrin et al., 2004).
Because of concerns that the relatively high exposure to corifollitro-
pin alfa during the ﬁrst days of stimulation might initiate an early rise of
LH (Devroey et al., 2004), all patients in this trial started treatment
with ganirelix on stimulation day 5. This ﬁxed start of GnRH antagonist
co-treatment was considered advantageous from an efﬁcacy perspec-
tive as this may result in higher pregnancy rates, as well as from a
methodological point of view as this reduces variability in the
applied treatment regimens (Kolibianakis et al., 2004; Al-Inany et al.,
2005; Arce et al., 2005).
The corifollitropin alfa regimen used in this trial comprised a single
dose of corifollitropin alfa followed by daily doses of rFSH (as needed
up to a daily maximum of 200 IU). This corifollitropin regimen was
compared with a ﬁxed dose of 200 IU/day rFSH for the ﬁrst 7
days, but with the option to decrease the daily FSH dose in cases
when hyper-response was observed. Thus there was a difference in
patient management options, with no option to adjust the dosing
during the ﬁrst week of stimulation in the corifollitropin arm. After cor-
ifollitropin alfa injection, serum FSH activity declines from stimulation
day 3 (Cmax) onwards, but further reduction of exposure during the
ﬁrst week of stimulation cannot be attained.
The validity of the claimed efﬁcacy and safety data of this trial are
limited to the study population only. Patients with known risk
factors for a hyper-response, such as patients with a history of
OHSS, with PCOS or with a high AFC (.20) were excluded from
the current trial. In addition, patients with a history of low ovarian
response in a previous IVF cycle were excluded. However, it should
be noted that 74% of the patients included in this trial underwent
their ﬁrst IVF cycle for which the ovarian response is less predictable
and will still include low- and high responder patients.
In this large cohort of (potential) normal responder patients, corifol-
litropin alfa has been shown to be well tolerated and non-immunogenic.
In line with the higher ovarian response, the observed incidence of
OHSS was higher in the corifollitropin alfa group, but the difference
was not signiﬁcant. Our study was not sufﬁciently powered to detect
an underlying difference in the incidence of OHSS, and therefore its
actual presence cannot be excluded. In line with the recruitment of
slightly more follicles by corifollitropin alfa, dose reductions during
stimulation were more frequently made in the corifollitropin alfa
group than in the reference group. Clearly, a minority of subjects
required a dose reduction on stimulation day 6 or 7, which may have
affected the ovarian response in the rFSH group rather than in the cor-
ifollitropin alfa group in which only the placebo was reduced.
Appropriate clinical monitoring and lowering or withholding the
daily rFSH dose to complete the cycle, as well as lowering or withhold-
ing the dose of hCG to trigger ﬁnal oocyte maturation, or cryopreser-
vation of all embryos obtained are options which can be considered as
part of patient management to minimize the risk of OHSS (Delvigne
and Rozenberg, 2002).
Owing to the double-blind design of the trial, requiring all patients
to be treated with an equal number of injections, no comparative data
could be collected on perceived patient convenience or preference for
the corifollitropin alfa regimen. Since a single injection of corifollitropin
alfa replaces the ﬁrst seven daily injections of rFSH during ovarian
stimulation, the intuitive advantages of such a simpler treatment
regimen are obvious, but need to be conﬁrmed in clinical practice.
In addition to patient preference, future controlled trials may
examine the efﬁcacy of corifollitropin alfa in (potential) poor respond-
ing patients as well as the safety in (potential) high responders.
In conclusion, in this study we tested the efﬁcacy (in terms of
ongoing pregnancy rates) of substituting the ﬁrst 7 daily doses of
rFSH with a single injection of corifollitropin alfa in women undergoing
ovarian stimulation for IVF/ICSI using rFSH and GnRH antagonists.
Our data demonstrate that a single corifollitropin alfa injection
results in an ongoing pregnancy rate which is equal to that of a daily
rFSH regimen. Combined with appropriate patient selection and
state-of-the-art clinical management during the stimulation phase of
the treatment cycle, corifollitropin alfa potentially offers an attractive
new treatment option for patients undergoing ovarian stimulation
during ART.
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